Guardant Health Secures New Commercial Payor Coverage for Liquid Biopsy Cancer Profiling Test
With new coverage from Anthem Blue Cross and Blue Shield, Aetna, and Humana, the firm's Guardant360/Guardant360 CDx assay is now covered by all major commercial health insurers.
Guardant Health Pushing Hard to Contextualize CRC Screening Data as Core Business Chugs Along
The company is seeing continuing growth for its existing clinical products as it moves resources toward commercialization of its Guardant Shield CRC screening test.
UBS Initiates Coverage of Exact Sciences, Natera, Guardant Health
The investment bank gave Natera and Guardant Health a Buy rating and Exact Sciences a Neutral rating.
Guardant Health Gets Medicare Coverage for Liquid Biopsy Treatment Response Test
The test is designed to track circulating tumor DNA levels in blood samples, enabling clinicians to evaluate patient responses to immunotherapy.
Companies that built their business in tissue and blood-based DNA analyses are now exploring imaging technologies across a variety of fronts.